Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Cipla’s Verma Succeeds Kabi US Veteran Ducker As CEO

Guided by the firm’s ‘Vision 2026’ strategy, Fresenius Kabi has tapped Cipla executive Arunesh Verma to lead Fresenius Kabi USA, as former head John Ducker retires after 35 years.

Executive Changes Leadership

AEON Aims For Biosimilar Pathway For Lead Candidate In Cervical Dystonia

California-based clinical-stage firm AEON Biopharma has announced a strategic redirection for its lead product candidate – using the 351(k) biosimilar pathway, with the world-renowned Botox as the reference product.

Biosimilars Drug Review

South Africa Drops J&J Bedaquiline Scrutiny After Generic Market Opens Up

Johnson & Johnson’s actions to promote generic competition and lower the price for its crucial tuberculosis treatment, Sirturo (bedaquiline), have satisfied an investigation launched by South Africa’s Competition Commission.

Regulation Policy

Celltrion’s Xolair Biosimilar Reaches UK, Following Key US Filing

Celltrion has ticked off another major regulator as it continues to lead the pack of global developers for biosimilar Xolair.

Biosimilars Approvals

Xbrane Working Towards Q2 2025 US Ranibizumab Approval

Xbrane plans to refile its proposed biosimilar to Lucentis by the end of 2024, after the recent disappointment of a US FDA complete response letter. However, the goal requires its manufacturing partners to successfully execute remediation plans.

Biosimilars Strategy

Taiwan’s Tanvex Welcomes US Filgrastim Approval – After String Of CRLs

Tanvex Biopharma submitted an application for biosimilar filgrastim as far back as 2018. Now, after multiple setbacks, the firm has celebrated becoming a commercial-stage company in the US.

Approvals Biosimilars
See All
UsernamePublicRestriction

Register